• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LBPH

    Longboard Pharmaceuticals Inc.

    Subscribe to $LBPH
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: longboardpharma.com

    Recent Analyst Ratings for Longboard Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    9/10/2024$60.00Buy
    Truist
    7/1/2024$60.00 → $90.00Overweight
    Cantor Fitzgerald
    5/1/2024$36.00Outperform
    Robert W. Baird
    2/16/2024$40.00Buy
    Citigroup
    10/24/2023$16.00 → $35.00Overweight
    Cantor Fitzgerald
    4/27/2023$13.00Buy
    B. Riley Securities
    2/14/2022$14.00Outperform
    Wedbush
    See more ratings

    Longboard Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lynch Casey

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:29:28 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Le Goff Corinne

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:27:57 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sekhri Paul J

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:26:22 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schneider Phillip M

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:24:45 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aurentz Vincent

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:22:42 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Vice President & CMO Kaye Randall closing all direct ownership in the company (SEC Form 4)

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:21:02 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive VP and CFO Roberts Brandi

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:19:21 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Lind Kevin Robert closing all direct ownership in the company (SEC Form 4)

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      12/2/24 7:17:15 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CMO Kaye Randall exercised 30,554 shares at a strike of $6.00, increasing direct ownership by 171% to 48,474 units (SEC Form 4)

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      11/19/24 8:13:58 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Lind Kevin Robert exercised 12,808 shares at a strike of $3.12 and gifted 80,000 shares, decreasing direct ownership by 16% to 363,740 units (SEC Form 4)

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      11/13/24 8:48:14 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CMO Kaye Randall bought $2,482 worth of shares (100 units at $24.82), sold $580,891 worth of shares (16,767 units at $34.64) and exercised 16,667 shares at a strike of $4.35 (SEC Form 4)

      4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

      8/13/24 6:01:53 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.

      15-12G - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/12/24 8:10:02 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Longboard Pharmaceuticals Inc.

      POSASR - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/10/24 3:53:35 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW WD filed by Longboard Pharmaceuticals Inc.

      RW WD - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/10/24 3:40:14 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.

      EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/10/24 12:15:08 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.

      EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/10/24 12:15:05 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.

      EFFECT - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/10/24 12:15:04 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW filed by Longboard Pharmaceuticals Inc.

      RW - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/2/24 11:30:14 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.

      S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/2/24 9:11:14 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.

      S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/2/24 9:11:15 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Longboard Pharmaceuticals Inc.

      S-8 POS - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

      12/2/24 9:11:15 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

      DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. "The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a

      11/12/24 8:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

      Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a stra

      11/7/24 4:01:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

      The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini

      10/14/24 6:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 56,000 shares of its common stock (the "Common Stock") and 35,000 restricted stock units ("RSUs") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs were granted on September 30, 2024 (the "Grant Date"

      10/4/24 4:01:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

      First sites activated with a number of additional rapid-start sites being activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. "We are thrilled to announce the initiation of our global Phase 3 DEEp Program with our first sites activated and multiple additional sites primed for activation within the next couple of weeks

      9/26/24 8:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

      U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Rare Pediatric Disease designation and Orphan Drug designation for its investigational drug bexicaserin for the treatment of Dravet syndrome. "We are thrilled to receive both Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome. As the first company to receive Breakthrough Therapy

      9/19/24 8:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

      Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period Favorable safety and tolerability results continue to be observed Data to be presented at the 15th European Epilepsy Congress in Rome, Italy Full 12-month OLE dataset expected early next year Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Develop

      9/8/24 6:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to eleven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 203,500 shares of its common stock (the "Common Stock") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted on August 31, 2024 (the "Grant Date") and have an exercise price of $36.08 per share, wh

      9/6/24 4:01:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

      Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate in four upcoming investor conferences. CONFERENCE DETAILS: Event: Wells Fargo Healthcare Conference Details: Hosting investor meetings on Thursday, September 5, 2024, in Boston, MA Event: H.C. Wainwright Global Investment Conference Details: Presenting in a fireside chat format on Tuesday, September 10, 2024, at 12:00 PM ET and hosting investor meetings in New York, NY Event: Baird's Global Healthcare Conference Details: Presenting in a fireside c

      8/28/24 4:00:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/14/24 3:10:34 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/14/24 1:22:40 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/12/24 3:59:14 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/8/24 5:15:02 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/7/24 9:26:47 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/7/24 9:12:22 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      11/4/24 1:25:47 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longboard Pharmaceuticals Inc.

      SC 13G - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      7/15/24 4:17:56 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      3/11/24 8:19:04 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

      2/14/24 3:04:09 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Longboard Pharmaceuticals with a new price target

      Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00

      9/10/24 7:53:02 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Longboard Pharmaceuticals with a new price target

      Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously

      7/1/24 12:54:07 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Longboard Pharmaceuticals with a new price target

      Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00

      5/1/24 6:27:25 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Longboard Pharmaceuticals with a new price target

      Citigroup initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      2/16/24 7:28:42 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Longboard Pharmaceuticals with a new price target

      Cantor Fitzgerald resumed coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $35.00 from $16.00 previously

      10/24/23 6:13:42 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Longboard Pharmaceuticals with a new price target

      B. Riley Securities initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $13.00

      4/27/23 6:39:33 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Longboard Pharmaceuticals with a new price target

      Wedbush initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $14.00

      2/14/22 9:20:38 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI Group initiated coverage on Longboard Pharmaceuticals with a new price target

      Evercore ISI Group initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $35.00

      4/7/21 6:21:13 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Longboard Pharmaceuticals with a new price target

      Guggenheim initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $27.00

      4/6/21 7:38:05 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Longboard Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $32.00

      4/6/21 7:15:46 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer

      SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade

      3/21/22 4:01:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

      Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) --  Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ

      3/3/22 4:05:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

      SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs," stated Kevin R. Lind, Longboard's President and Chief Executive Officer.

      11/17/21 8:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Longboard Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

      The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini

      10/14/24 6:30:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P

      8/1/24 4:01:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

      Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we

      7/29/24 9:15:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

      Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved Favorable safety and tolerability results Longboard is rapidly moving forward with preparations for its global Phase 3 program Conference call and webcast to be held today at 8:30am ET Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline da

      1/2/24 8:00:00 AM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

      • Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-class, oral, novel, 5-HT2C receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes. Conference Call and Webcast Details

      1/1/24 4:47:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023

      Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day. CONFERENCE CALL DETAILS: Live Call Participation: To join the live call by phone, please pre-register via this link, complete the brief online registration form, and select your preferred method for joining the call. Upon registering you will receive the dial-in info and a unique PIN to join the call, as well as an email confirma

      2/23/23 4:31:00 PM ET
      $LBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

      Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharma

      3/24/22 4:26:10 PM ET
      $LBPH
      $LCTX
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)